Director Kathy Palmer Ordonez of Pacific Biosciences of California, Inc. filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 18,595 shares of common stock through Morgan Stanley Smith Barney LLC.
Key Highlights
- Seller: Kathy Palmer Ordonez, identified in the filing as a Director of Pacific Biosciences of California, Inc.
- Shares proposed for sale: 18,595 shares of common stock, with an aggregate market value of $33,093.52.
- Approximate sale date: November 17, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.
- Shares outstanding: 312,926,730 shares of common stock, according to the filing.
- Acquisition origin: Shares were acquired on February 15, 2022, via restricted stock vesting under a registered plan, with payment described as services rendered.
- No prior sales: The filing reports nothing to disclose for securities sold during the past three months.
Pacific Biosciences Director Discloses Proposed Rule 144 Share Sale
Pacific Biosciences of California, Inc. (NASDAQ:PACB), headquartered at 1305 O'Brien Drive, Menlo Park, California, is the issuer identified in the filing. Director Kathy Palmer Ordonez submitted a Form 144 notice of proposed sale of securities pursuant to Rule 144 under the Securities Act of 1933, dated November 17, 2026.
According to the filing, the 18,595 shares of common stock proposed for sale carry an aggregate market value of $33,093.52. The shares were originally acquired on February 15, 2022, through restricted stock vesting under a registered plan, with the nature of payment listed as services rendered. The issuer is named as the person from whom the shares were acquired. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, on the NASDAQ exchange.
The filing states that there is nothing to report regarding securities sold during the past three months by Ordonez. The total shares of common stock outstanding are reported as 312,926,730. By signing the notice, the filer represented, as stated in the form, that she "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed."
What Was Disclosed
A Form 144 notice was filed by Director Kathy Palmer Ordonez on November 17, 2026, disclosing a proposed sale of 18,595 shares of Pacific Biosciences of California common stock, valued at $33,093.52, acquired through restricted stock vesting in February 2022.



Please wait processing your request...